how quickly do you lose weight with glp-1 Before & After Semaglutide Loss GLP-1 and weight loss injections

CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031

Still, there is no universal day when side effects begin or a guarantee that they disappear by month 3

Novo Nordisk has also cited indirect comparison data suggesting that fewer patients discontinued oral semaglutide due to side effects compared with orforglipron, though the companies and independent commentators note the significant methodological limitations of such comparisons in the absence of a head-to-head obesity trial

Between 8% and 10% of Americans are using GLP-1s, while 30%-35% are interested in using them